HSCT, or Hematopoietic Stem Cell Transplantation, the only scientifically demonstrated treatment that has shown a curative effect for Multiple Sclerosis.
This is not a new medical procedure; it has been performed worldwide since the 1960’s for treatment of cancer has been used successfully to cure several types of autoimmune disorders since the early 1990’s (such as MS, scleroderma, rheumatoid arthritis, lupus, CIDP and others; 23 diseases in total).
Clinical research into HSCT as a treatment for autoimmune diseases (and MS specifically) began in the early 1990’s in Europe.
The first US clinical based trial work with HSCT for MS began in the 1990s with Dr. Richard Burt after he noticed that leukemia patients who had received a treatment to wipe out their immune systems, needed to be re-immunized against diseases such as measles and mumps. Although the patients in question had been vaccinated as children, the therapy for their blood cancer had erased this cellular memory. Dr Burt then made the realization that this treatment approach should be used in autoimmune diseases such as Multiple Sclerosis.
In the United States, HSCT is still in an ongoing clinical trial with the expected finish date of 2021.